Diazoxide, Prednisone & Treatment Options

Insulinoma in dogs is a functional tumor of the pancreatic beta cells that secretes excessive insulin, causing dangerously low blood sugar (hypoglycemia). Most commonly diagnosed in medium-to-large breeds between 9 and 12 years of age, this condition demands a multi-layered medical approach — especially when surgery isn't an option or as a bridge to surgical intervention.

This guide covers the primary prescription medications veterinarians use to manage insulinoma in dogs, with detailed dosing, side effect profiles, monitoring schedules, and cost expectations for 2026.

What Is Insulinoma and Why Medication Is Often Necessary

An insulinoma is a neuroendocrine tumor arising from the beta cells of the pancreas. These cells normally produce insulin in response to blood glucose levels. In dogs with insulinoma, the tumor cells produce insulin inappropriately — regardless of how low blood sugar has already dropped. The result is recurrent, sometimes life-threatening hypoglycemic episodes.

According to the Merck Veterinary Manual, approximately 95% of canine insulinomas are malignant at diagnosis, with metastasis to regional lymph nodes, liver, or mesentery common. While surgical removal (partial pancreatectomy) offers the best chance at extending survival time, many dogs are not surgical candidates due to tumor location, metastatic spread, or owner financial constraints.

Medical management becomes the primary strategy in these cases, and even surgical candidates typically require medication before and after the procedure to stabilize blood glucose levels.

Primary Medications Used to Treat Insulinoma in Dogs

Three main drugs form the backbone of medical management for insulinoma in dogs. Your veterinarian may use one or combine several depending on tumor burden, symptom severity, and your dog's overall health.

1. Diazoxide (Proglycem®)

Drug class: Benzothiadiazine derivative; potassium channel activator

FDA-approved veterinary use: Management of hypoglycemia associated with insulinoma in dogs

Mechanism of action: Diazoxide directly inhibits insulin secretion from pancreatic beta cells by opening ATP-sensitive potassium channels, which hyperpolarizes the cell membrane and prevents calcium-dependent insulin release. It also stimulates hepatic gluconeogenesis and glycogenolysis (glucose production and release from the liver), and inhibits peripheral glucose uptake by tissues.

2. Prednisone / Prednisolone

Drug class: Glucocorticoid (corticosteroid)

FDA-approved veterinary use: Anti-inflammatory and immunosuppressive agent; used off-label for insulinoma management

Mechanism of action: Glucocorticoids promote gluconeogenesis in the liver, decrease peripheral tissue sensitivity to insulin, and stimulate glycogen storage. These effects collectively raise blood glucose levels. For insulinoma patients, prednisone serves as both a glucose-elevating agent and a palliative anti-inflammatory for metastatic disease.

3. Octreotide (Sandostatin®)

Drug class: Somatostatin analog (synthetic peptide)

FDA-approved veterinary use: None specifically for dogs; used off-label

Mechanism of action: Octreotide binds to somatostatin receptors (particularly SSTR2 and SSTR5) on insulinoma cells, directly suppressing insulin secretion. It also slows gastrointestinal motility and inhibits growth hormone and glucagon release, creating a complex metabolic effect that generally favors higher blood glucose in insulinoma patients.

Typical Dosage Ranges for Insulinoma Medications

The following dosages are general veterinary guidelines. Your veterinarian will determine the exact dose for your dog based on body weight, symptom severity, blood glucose monitoring results, and concurrent health conditions. Never adjust these dosages without veterinary direction.

Dose calculation example (Diazoxide): A 25 kg (55 lb) Labrador starting at 5 mg/kg would receive 125 mg per dose, given twice daily (250 mg total daily). If blood glucose remains low, the veterinarian may titrate upward in increments of 5 mg/kg every 3–5 days, monitoring closely for side effects.

Administration Instructions

Diazoxide: Give with food to minimize gastrointestinal upset and reduce the risk of drug-induced hypotension. The oral suspension (Proglycem®) should be shaken well before each use. If using compounded capsules, ensure consistent compounding pharmacy for reliable absorption. Duration is typically lifelong for non-surgical candidates.

Prednisone: Administer with food to reduce gastric irritation. Morning dosing is preferred for once-daily protocols to align with the dog's natural cortisol rhythm. Tapering is required if discontinuing after more than 2–3 weeks of use — abrupt withdrawal can cause an Addisonian crisis (adrenal insufficiency).

Octreotide: Administered via subcutaneous injection. Your veterinary team will train you on proper injection technique, site rotation, and syringe handling. The medication must be refrigerated (36–46°F / 2–8°C) and protected from light. Vials typically remain stable for 14 days after first puncture when refrigerated.

Side Effects: What to Expect and When to Worry

Each medication carries a distinct side effect profile. Understanding the difference between expected, manageable side effects and emergency warning signs is critical for insulinoma management.

Drug Interactions and Contraindications

Managing insulinoma in dogs often involves concurrent medications, making drug interaction awareness essential. Always provide your veterinarian with a complete list of every medication, supplement, and over-the-counter product your dog receives.

Drug Interaction Grid

Contraindications: Dogs Who Should NOT Receive These Medications

Diazoxide should NOT be used in dogs with:

• Known hypersensitivity to thiazide or sulfonamide-derived drugs
• Severe congestive heart failure (fluid retention exacerbates CHF)
• Severe hepatic dysfunction (impaired drug metabolism)
• Functional hypoglycemia not caused by insulinoma (e.g., hunting dog hypoglycemia, xylitol toxicity) — different treatment protocols apply

Prednisone should NOT be used in dogs with:

• Active systemic fungal infections
• Uncontrolled diabetes mellitus (paradoxical comorbidity — requires careful risk-benefit analysis)
• Active GI ulceration
• Concurrent NSAID therapy (absolute contraindication)
• Known hyperadrenocorticism (Cushing's disease)

Octreotide should NOT be used in dogs with:

• Known hypersensitivity to somatostatin analogs
• Severe cardiac conduction abnormalities (use with extreme caution)
• Gallbladder disease or biliary obstruction (relative contraindication)

Monitoring Schedule: Blood Work and Follow-Up Visits

Effective management of insulinoma in dogs requires structured monitoring. Your veterinarian will establish a schedule tailored to your dog's specific protocol, but the following represents a typical monitoring framework based on current veterinary endocrinology guidelines.

According to the AVMA, consistent monitoring compliance significantly improves quality of life and survival time in dogs managed medically for insulinoma. Dogs on diazoxide monotherapy with diligent monitoring have reported median survival times of 12–14 months, compared to approximately 6 months without medical management.

Cost Expectations and Generic Availability

Managing insulinoma in dogs is a significant financial commitment. Understanding costs upfront helps you plan realistically and discuss options openly with your veterinarian.

Tip: Discuss compounded medication options with your veterinarian. Many veterinary compounding pharmacies (such as Wedgewood Pharmacy or Chewy's compounding service) can prepare diazoxide in flavored chew treats or capsules at 40–60% less than brand-name pricing, while maintaining bioequivalence when sourced from PCAB-accredited facilities.

Dietary Management: The Overlooked Third Pillar

Medication alone rarely achieves optimal blood glucose control in dogs with insulinoma. Nutritional strategy is the third pillar of management alongside pharmaceutical intervention and monitoring.

Key dietary principles for insulinoma patients:

• Feed 4–6 small meals per day rather than 1–2 large meals to avoid post-prandial insulin spikes
• High-protein, moderate-fat, complex-carbohydrate diet — simple sugars and high-glycemic foods trigger insulin release and should be strictly avoided
• Recommended commercial diets: Look for AAFCO complete-and-balanced formulations with a named protein as the first ingredient and no added sugars, corn syrup, or high-glycemic grains. Prescription diets such as Hill's w/d or Royal Canin Veterinary Diet Gastrointestinal may be recommended by your veterinarian
• Avoid semi-moist foods — these often contain propylene glycol and simple sugars that cause rapid glucose fluctuations
• Never fast an insulinoma dog — even overnight fasting can trigger hypoglycemic episodes. A small bedtime snack of complex carbohydrates with protein (e.g., a tablespoon of plain canned pumpkin with a teaspoon of cooked chicken) can help maintain overnight glucose levels

Consult a veterinary nutritionist (board-certified through the ACVN) if you're considering a homemade diet for long-term management. Nutritionally incomplete homemade diets can create secondary deficiencies that compound the challenges of managing insulinoma.

Missed Doses, Overdoses, and Emergency Protocols

If a Dose Is Missed

Diazoxide: If you remember within 4 hours of the scheduled time, give the missed dose. If more than 4 hours have passed, skip it and resume the next scheduled dose. Never double-dose. Monitor your dog closely for hypoglycemic signs (weakness, trembling, disorientation) over the next 6–8 hours and offer a small meal.

Prednisone: Give the missed dose as soon as you remember on the same day. If it's the next day, resume the normal schedule — do not double up. A single missed dose of prednisone is unlikely to cause acute problems, but repeated missed doses can destabilize blood glucose control.

Octreotide: Administer the missed dose as soon as remembered unless the next dose is due within 4 hours. In that case, skip and resume the regular schedule.

If an Overdose Occurs

Contact your veterinarian or an emergency veterinary clinic immediately. For diazoxide overdose, the primary concerns are severe hyperglycemia, hypotension, and tachycardia. For prednisone overdose, acute signs may include vomiting, GI bleeding, and extreme polydipsia/polyuria. For octreotide overdose, paradoxical hypoglycemia or cardiac arrhythmias are possible.

Keep these emergency numbers accessible:

• ASPCA Animal Poison Control: (888) 426-4435 (24/7, consultation fee applies)
• Pet Poison Helpline: (855) 764-7661
• Your local emergency veterinary hospital (save the number in your phone now)

How Long Will My Dog Need Medication?

For dogs managed medically (without surgery), medication for insulinoma is typically lifelong. The tumor does not regress with medication alone — these drugs manage the downstream effects (hypoglycemia) rather than treating the tumor itself.

Over time, many dogs require dose escalation as the tumor grows and produces more insulin. This is why monitoring is so critical — a dose that worked at month 2 may be insufficient by month 6. Your veterinarian will adjust based on blood glucose trends, not just clinical signs.

For dogs that undergo surgical removal of the insulinoma, medications may be needed for 2–6 weeks post-operatively while the remaining pancreatic tissue recalibrates insulin production. Some dogs develop transient diabetes mellitus after surgery, requiring temporary insulin therapy — the opposite problem, but manageable with veterinary guidance.

Median survival time with medical management alone ranges from 6 to 18 months depending on tumor burden, metastatic status, and response to therapy. Dogs that undergo surgery followed by medical management may survive 12–38 months, according to data cited in the Merck Veterinary Manual.

Alternatives to Standard Medical Management

While diazoxide, prednisone, and octreotide represent the primary pharmacological toolkit, several additional or alternative approaches exist:

Surgical intervention (partial pancreatectomy): The gold standard when feasible. Removes the primary tumor and any visible metastases. Cost: $5,000–$12,000 depending on complexity and facility. Offers the longest survival times but carries risks of post-operative pancreatitis, diabetes, and incomplete resection.

Streptozocin (chemotherapy): A pancreatic beta-cell toxin that has shown limited efficacy in dogs. Used at some veterinary oncology centers as an adjunct to surgery or for metastatic disease. Significant nephrotoxicity limits its use. Administered only by board-certified veterinary oncologists.

Alloxan: Another beta-cell cytotoxic agent. Historically used but largely abandoned due to severe nephrotoxicity and inconsistent results. Rarely available in current veterinary practice.

Toceranib phosphate (Palladia®): A tyrosine kinase inhibitor that has shown anecdotal benefit in some insulinoma cases with metastatic disease. Not FDA-approved for this indication, but some veterinary oncologists prescribe it off-label. Cost: $300–$700/month.

Everolimus (mTOR inhibitor): Emerging evidence from human insulinoma treatment is prompting investigation in veterinary oncology. Currently limited to specialty centers and clinical trials.

Dietary management alone: In very early or mild cases, frequent small meals with complex carbohydrates may provide temporary stabilization. This is not a substitute for medication in moderate-to-severe cases and should never replace veterinary-directed treatment.

Frequently Asked Questions About Insulinoma Medications

Can I use human diazoxide for my dog?

While the active ingredient is the same, human-formulated diazoxide tablets are dosed differently and may contain excipients not ideal for canine use. Your veterinarian can prescribe veterinary-labeled Proglycem® or have a compounding pharmacy prepare an appropriate formulation. Never substitute human medications without veterinary guidance.

Will my dog's insulinoma medication cure the tumor?

No. Diazoxide, prednisone, and octreotide manage the hypoglycemia caused by the tumor but do not shrink or eliminate the tumor itself. Only surgical removal offers the possibility of reducing tumor burden, and even surgery is rarely curative due to the high rate of metastasis at diagnosis.

My dog is on prednisone for insulinoma — is the increased drinking and urination normal?

Yes, increased thirst and urination are expected side effects of prednisone at the doses used for insulinoma management. However, if you notice signs of a urinary tract infection (straining, blood in urine, accidents in a previously house-trained dog), contact your veterinarian — immunosuppressive doses of prednisone increase UTI risk.

How do I give my dog a subcutaneous octreotide injection at home?

Your veterinary team will provide hands-on training before sending you home with octreotide. Generally: draw up the prescribed dose, lift a fold of loose skin over the shoulder or flank area, insert the needle at a 45-degree angle into the subcutaneous space, and depress the plunger. Rotate injection sites daily to prevent tissue irritation. Most dogs tolerate this well with positive reinforcement (treats and praise during and after injection).

Is pet insurance likely to cover insulinoma treatment?

If your dog was enrolled in a pet insurance plan before the insulinoma diagnosis, most comprehensive plans (Trupanion, Healthy Paws, Nationwide) cover diagnostic workups, medications, surgery, and follow-up monitoring. Pre-existing condition exclusions apply. Expect annual payouts that may approach or exceed typical policy maximums ($10,000–$30,000/year depending on your plan). Review your policy's annual and lifetime limits before beginning treatment.

What are the signs that medical management is no longer working?

Escalating frequency of hypoglycemic episodes despite dose increases, inability to maintain blood glucose above 50 mg/dL even on maximum diazoxide and prednisone doses, development of new metastatic lesions on imaging, or declining body condition despite adequate caloric intake all suggest that medical management is reaching its limits. Discuss palliative care options and quality-of-life assessments with your veterinarian at this stage.